Addex Therapeutics (ADXN) FCF Margin (2019 - 2024)
Addex Therapeutics (ADXN) posted FCF Margin of 354689630316.51% for Q4 2024, up 3669.24% sequentially from 9937390732.37% in Q3 2024, and up 34989087175466.0% YoY from N/an in Q1 2024.
Addex Therapeutics (ADXN) FCF Margin (2019 - 2024) Analysis & Trends
Addex Therapeutics has reported FCF Margin for 6 years, with the latest figure at 354689630316.51% in Q4 2024.
- Quarterly FCF Margin rose 34989087175466.0% year-over-year to 354689630316.51% in Q4 2024, while the trailing twelve-month figure through Dec 2025 was 146105858.12% (up 18029240801.0% YoY) and the FY2025 annual result came in at 7243.82%, down 591375.0% from the prior year.
- FCF Margin grew to 354689630316.51% in Q4 2024 per ADXN's latest filing, from 9937390732.37% in the prior quarter.
- Over five years, FCF Margin peaked at 354689630316.51% in Q4 2024 and troughed at 9937390732.37% in Q3 2024.
- A 5-year average of 17450868174.16% and a median of 584.27% in 2022 frame the typical range for FCF Margin.
- The widest YoY moves for FCF Margin: up 2000000000 bps in 2024, down 2000000000 bps in 2024.
- Over 5 years, FCF Margin stood at 16.35% in 2020, then sank by 679 bps to 94.62% in 2021, then sank by 448 bps to 518.71% in 2022, then surged by 925140749 bps to 4798758561.85% in 2023, then surged by 7291 bps to 354689630316.51% in 2024.
- According to Business Quant data, FCF Margin over the past three periods registered 354689630316.51%, 9937390732.37%, and 1903566234.88% for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Addex Therapeutics | 515.38 Mn | 515.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 354,689,630,316.51% |
| Sep 30, 2024 | -9,937,390,732.37% |
| Jun 30, 2024 | 1,903,566,234.88% |
| Mar 31, 2024 | -939,857,375.36% |
| Dec 31, 2023 | 4,798,758,561.85% |
| Sep 30, 2023 | -686,976,593.75% |
| Jun 30, 2023 | -810,348,077.84% |
| Mar 31, 2023 | -470.55% |
| Dec 31, 2022 | -518.71% |
| Sep 30, 2022 | -657.01% |
| Jun 30, 2022 | -3,179.79% |
| Mar 31, 2022 | -2,042.10% |
| Dec 31, 2021 | -94.62% |
| Sep 30, 2021 | -372.04% |
| Jun 30, 2021 | -649.83% |
| Mar 31, 2021 | -327.61% |
| Dec 31, 2020 | 16.35% |
| Sep 30, 2020 | -9,379.36% |
| Jun 30, 2020 | -716.15% |
| Mar 31, 2020 | -459.27% |